



Embase

The 2018 list of Journals included in Embase is now available. [Download the list](#)

Embase® [Search](#) [Emtree](#) [Journals](#) [Results](#) [My tools](#) [Register](#) [Login](#) [🔔](#) [🔍](#) [☰](#)

Quick Search [Select Language | ▼](#)

[Quick](#) [PICO](#) [PV Wizard](#) [Advanced](#) [Drug](#) [Disease](#) [Device](#) [Article](#) [Authors](#) [Search tips](#)

Quick search

AND [Show 0 results >](#)

AND

AND

[+ Add search field](#)

Limit to:

Publication years (including): to

Records added to Embase (including end date):

Evidence Based Medicine

Cochrane Review Controlled Clinical Trial

Systematic Review Randomized Controlled Trial

Meta Analysis

Embase er en medicinsk bibliografisk database som indekserer over 22 millioner poster fra 1947 og frem, med en vækst på over 1 million poster årligt. De indekserede tidsskrifter dækker internationalt med over 7.500 peer-reviewed titler fra over 90 lande

Embase bliver opbygget ved hjælp af et kontrolleret emneordssystem, kaldet Emtree thesaurus. Emtree minder meget om MeSH i PubMed både hvad angår opbygning og indhold. Embase indeholder tre databaser:

- Embase database: indeholder biomedicinsk litteratur fra 1974 to present og frem
- MEDLINE: Indekserer tidsskrifter fra 1966 til nu
- Embase Classic: Embase back files der dækker næsten 2 millioner biomedicinske citationer fra over 3,000 international titler mellem 1947 og 1973.

Trunkering: * = erstatter nul eller flere bogstaver

Maskering: ? = til erstatning af ét bogstav

Hjælp: ? - øverst til højre i skærbilledet – indeholder en mængde gode tutorials

Yderligere information om søgning https://service.elsevier.com/app/answers/detail/a_id/16422/c/10545/supporthub/embase/

Her er et eksempel på en Quick søgning på ordet Stroke:

The screenshot shows a 'Quick Search' interface with a search bar containing 'strok'. Below the search bar, there are several search filters: 'Journal name', 'Author name', and 'Author's first name'. To the right, a list of search results is displayed, including 'stroke: use: cerebrovascular accident' (286,025), 'stroke patient' (24,737), 'stroke sufferer: use: stroke patient' (24,737), 'stroke sufferers: use: stroke patient' (24,737), 'stroke volume: use: heart stroke volume' (24,123), 'stroke unit' (4,303), and 'stroke care unit: use: stroke unit' (4,303).

Og du finder ud af, at artikler om stroke i Embase gemmer sig under det kontrollerede emneord Cerebrovascular accident.

Ved denne metode søges der automatisk på selve begrebet Cerebrovascular accident og på de mere specifikke begreber, der knytter sig til Cerebrovascular accident; cardioembolic stroke, experimental stroke, lacunar stroke :

'cerebrovascular accident'/exp OR 'cerebrovascular accident'

En *Explosion /exp* søgning er bredere end en frase søgning ” .

Resultat af søgning kan udvides ved klik på Expand under results Filter. Dette resulterer i en bred vifte af facetter bl.a. Drugs, Diseases, Devices, Floating subheadings, Age og Gender. Disse facetter kan bruges til at indsnævre søgningen i den relevante retning

The screenshot shows a search results page for the query 'cerebrovascular accident'/exp OR 'cerebrovascular accident'. The search results are displayed in a list format, with the first five results visible. The 'Results Filters' section is expanded, showing a Venn diagram for 'Sources' (Embase and MEDLINE) and a list of 'Drugs' and 'Diseases' with their respective counts. The 'Drugs' list includes acetylsalicylic acid (22952), warfarin (14965), anticoagulant agent (14584), placebo (12773), clopidogrel (10613), unclassified drug (8698), hydroxymethylglutaryl coenzyme a reductase inhibitor (8678), and heparin (8215). The 'Diseases' list includes cerebrovascular (282708).

Hvis du ønsker se nærmere på en af artiklerne, klikkes på titlen hvilket trækker hele posten frem

Embase Search Entree Journals Results My tools Register Login

Record Details Select Language

Session Results / Record 1 of 287,643 [Full record]

Record Similar records Add to clipboard Email Record Add All to Clipboard Print Back to results Link

Original Title
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: Patient selection and perspectives
Anagnostou T, Litzow M R

Blood and Lymphatic Cancer: Targeted Therapy 2018 8(1):1-7

Go to publisher for the full text [Via University Colleges Full Text](#)

Original Abstract
Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are either resistant or unable to tolerate another tyrosine kinase inhibitor. Its US Food and Drug Administration approval was based on results from long-term follow-up of the pivotal Phase II PACE trial, which demonstrated deep and durable molecular responses in the treated patients. Despite the remarkable responses, ponatinib has been associated with high frequency of severe vascular events, which led to its withdrawal from the market in 2013. Following analysis of the risk factors of patients who developed vascular side effects, ponatinib was reintroduced in the market 1 year later with specific dose-reduction recommendations and carrying a black box warning. Thus, careful patient selection with identification of patients whose potential benefit from ponatinib exceeds the potential risks associated with its use is crucial. Ongoing and future studies are focusing on earlier detection of mutations, strategies to minimize side effects, and potential expansion of the treatment indications. Clinical trials testing the safety and efficacy of ponatinib as frontline therapy are ongoing.
© 2018 Anagnostou and Litzow.

Drug Terms
cyclophosphamide, dexamethasone, doxorubicin, imatinib, ponatinib, vincristine

Disease Terms
acute lymphoblastic leukemia, extrinsic, bone marrow suppression, gastrovascular accident, chronic myeloid leukemia, autologous graft versus host disease, graft versus host reaction, heart infection, infection, pancreatitis, peripheral vascular disease, Philadelphia 1 chromosome, Philadelphia chromosome-positive acute lymphoblastic leukemia, rash, side effect, skin disease, thrombocytopenia, venous thromboembolism

Other Terms
allogeneic hematopoietic stem cell transplantation, cancer chemotherapy, cancer growth, cancer recurrence, cancer resistance, cancer risk, disease association, drug efficacy, drug safety, follow up, human, multicenter study (topic), overall survival, phase 1 clinical trial (topic), phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, progression free survival, propensity score, prospective study, randomized controlled trial (topic), retrospective study, review, treatment outcome, treatment response

Author keywords
Acute lymphoblastic leukemia, Chronic myeloid leukemia, Patient selection, Ponatinib

Correspondence Address
Litzow M.R. Mayo Clinic Rochester 200 First Street, Rochester, MN, United States.

Author Address
Anagnostou T, Litzow M.R. Mayo Clinic Rochester 200 First Street, Rochester, MN, United States.

Copyright
Copyright 2018 Elsevier B.V. All rights reserved.

Her kan man så brede ud med similar records – eller gå direkte til fuldteksten ved at klikke på linket "Via University Colleges Full Text"